Get started
Author

Kerstin R. Allen

Minimal Clinically Important Differences in the Erectile Function Domain of the International Index of Erectile Function Scale
2011 · Raymond C. Rosen, Kerstin R. Allen, et al. · European Urology · 460
Interstage mortality after the Norwood procedure: Results of the multicenter Single Ventricle Reconstruction trial
2012 · Nancy S. Ghanayem, Kerstin R. Allen, et al. · Journal of Thoracic and Cardiovascular Surgery · 372
PDF
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
2017 · Steven M. Horwitz, Raphael Koch, et al. · Blood · 289
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies
2017 · Ian W. Flinn, Susan O’Brien, et al. · Blood · 252
Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder
2023 · Sean J. Pittock, Michael Barnett, et al. · Annals of Neurology · 214
PDF
Survival Data and Predictors of Functional Outcome an Average of 15 Years after the Fontan Procedure: The Pediatric Heart Network Fontan Cohort
2014 · Andrew M. Atz, Victor Zak, et al. · Congenital Heart Disease · 74
PDF
Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
2014 · Susan O'Brien, Manish Patel, et al. · Blood · 65
Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study
2018 · Susan O'Brien, Manish Patel, et al. · American Journal of Hematology · 60
PDF
a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL
2014 · Ian Flinn, Yasuhiro Oki, et al. · Blood · 48
Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, Shows Activity in Patients with Relapsed/Refractory T-Cell Lymphoma
2014 · Steven M. Horwitz, Pierluigi Porcu, et al. · Blood · 46
Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study
2018 · Ian W. Flinn, Manish Patel, et al. · American Journal of Hematology · 39
PDF
Clinical Activity of Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, in Patients Previously Treated with Ibrutinib
2014 · Pierluigi Porcu, Ian Flinn, et al. · Blood · 35
Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ, in patients with relapsed/refractory CLL.
2013 · Manish R. Patel, Brad S. Kahl, et al. · Journal of Clinical Oncology · 34
Superior cavopulmonary anastomosis timing and outcomes in infants with single ventricle
2012 · James F. Cnota, Kerstin R. Allen, et al. · Journal of Thoracic and Cardiovascular Surgery · 34
PDF
Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia
2013 · Ian Flinn, Manish Patel, et al. · Blood · 28
Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, in Patients with Advanced Hematologic Malignancies
2012 · Ian W. Flinn, Steven M. Horwitz, et al. · Blood · 23
Minimal Clinically Important Differences in the Vaginal Insertion and Successful Intercourse Items of the Sexual Encounter Profile
2011 · Andre B. Araujo, Kerstin R. Allen, et al. · The Journal of Sexual Medicine · 22
Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ, in patients with relapsed/refractory lymphoma.
2013 · Steven M. Horwitz, Ian Flinn, et al. · Journal of Clinical Oncology · 19
Challenges and successes of recruitment in the “angiotensin-converting enzyme inhibition in infants with single ventricle trial” of the Pediatric Heart Network
2012 · Nancy A. Pike, Victoria Pemberton, et al. · Cardiology in the Young · 13
Duvelisib, a PI3K-δ,γ inhibitor, in subjects with mild asthma
2015 · Tess Schmalbach, Rainard Fuhr, et al. · 11
Early clinical activity and pharmacodynamic effects of duvelisib, a PI3K-δ,γ inhibitor, in patients with treatment-naïve CLL.
2015 · Manish R. Patel, Susan Mary O'Brien, et al. · Journal of Clinical Oncology · 11
Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
2024 · Stephan Ortiz, Sean J. Pittock, et al. · Frontiers in Neurology · 10
PDF
Clinical and real-world pharmacovigilance data of meningococcal infections in eculizumab- or ravulizumab-treated patients
2023 · Sami Fam, Brian Werneburg, et al. · Journal of the Neurological Sciences · 5
PDF
Preliminary safety, pharmacokinetics, and pharmacodynamics of duvelisib plus rituximab or obinutuzumab in patients with previously untreated CD20+ follicular lymphoma.
2016 · Carla Casulo, Eric D. Jacobsen, et al. · Journal of Clinical Oncology · 5
1532 Minimal Clinically Important Differences (mcid) in the Erectile Function (ef) Domain of the International Index of Erectile Function (iief)
2011 · Raymond C. Rosen, Kerstin R. Allen, et al. · The Journal of Urology · 4
Works count: 55
Citation count: 2,190
H-index: 18
I10-index: 22
Year
Topic
Type